28 February 2020
Visiongain has launched a new pharma report Global Bioprocess Optimisation & Digital Biomanufacturing Market Forecast.
The Global market for bioprocess optimisation and digital biomanufacturing is favoured by the increasing global population which by 2050 will be predominately 65 years and above. There is also a growing demand for biologics drugs and biosimilar drugs which has compelled manufacturers to introduce technologies that would help bring the drugs to the market at a far more rapid pace than before.
The lead analyst of the report commented "The Bioprocess Optimization and Digital Manufacturing market is expected to witness a robust growth during the years of forecast owing to rise in biosimilars, growing complexity of drug manufacturing and patent expiry of blockbuster drugs coupled with rising cost containment pressure on biopharmaceutical players which is also expected to improve the uptake of digitally advanced products for manufacturing. With respect to the technology market, the analytical and process control technologies are expected to witness the highest growth during the forecast period. The bioreactors market is expected to foresee the highest growth during the forecast period."
Leading companies featured in the report include ABB, 3M Co., Danaher Corporation, Agilent Technologies, Applikon Technology, Sartorius Stedium Biotech, Shimadzu Corp., Siemens Healthcare and many others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
19 April 2021
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.